Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2017 | Clinicogenetic risk models to predict outcome of follicular lymphoma patients

Sarah Huet • 14 Jun 2017
ICML 2017
Follicular Lymphoma Rituximab

Sarah Huet, PharmD, PhD from the Centre Hospitalier Lyon-Sud, Pierre- Bénite, France discusses her work on clinicogenetic risk models for outcome of follicular lymphoma patients in the PRIMA trial. The clinicogenetic models combine clinical variables as well as genetic risk factors. Two risk models have been developed in the last two years to identify patients with aggressive disease and short remission times. These were evaluated in a cohort of patients from the PRIMA trial which looked at rituximab maintenance post immunotherapy. In addition, the added value of these new prognostic indexes were compared to the older models FLIPI 1 and FLIPI 2. This interview was recorded at the International Conference on Malignant Lymphoma (ICML) 2017 in Lugano, Switzerland.

More from Sarah Huet

1:01
Using models to predict progression in follicular lymphoma
Sarah Huet • 14 Jun 2017

Related Videos

1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
1:48
Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing
Gloria Iacoboni • 15 Apr 2024
0:55
Mosunetuzumab in untreated FL and MZL: a response-adapted trial
Ryan Lynch • 8 Dec 2023
3:32
BGB-16673, a novel BTK degrader, in patients with R/R B-cell malignancies
John Seymour • 8 Dec 2023
The content of VJHemOnc is intended for healthcare professionals